Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Posters

22P - HGF and c-Met expression in metastatic endometrial cancer

Date

06 Oct 2021

Session

e-Posters

Presenters

Olga Brieieva

Citation

Annals of Oncology (2021) 32 (suppl_6): S1345-S1371. 10.1016/annonc/annonc740

Authors

O. Brieieva1, O. Movchan2, L. Buchynska3

Author affiliations

  • 1 R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Science of Ukraine, Kiev/UA
  • 2 National Cancer Institute of the Ministry of Health of Ukraine, 3022 - Kiev/UA
  • 3 R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Science of Ukraine, 3022 - Kiev/UA
More

Abstract 22P

Background

HGF/c-Met is one of the signaling pathways that determine the invasiveness and metastatic potential of various cancers, however, its significance for the progression of endometrial cancer (EC) remains not entirely clear. The aim of this study was to investigate HGF and c-Met expression in tumours of EC patients in relation to the presence of metastasis.

Methods

The study was carried out retrospectively on 57 endometrial carcinomas including 32 samples from EC patients with metastasis. Protein expression was evaluated by immunohistochemistry using polyclonal antibody against HGF (PA5-83494, Invitrogene, Sweden) and monoclonal c-Met (EP1454Y, Bio SB, USA) for the percentage of stained cells (labeling index, %). Expression analysis was performed separately in epithelial tumour cells and fibroblasts of the surrounding stroma. Nonparametric Mann-Whitney U-test was used to compare differences between groups.

Results

The mean level of HGF expression in epithelial tumour cells was 18.5 ± 3.3%, in stromal fibroblasts – 14.8 ± 3.6%. The corresponding indices for c-Met were 17.5 ± 3.3 and 18.5 ± 3.8%, respectively. No statistically significant difference was observed in HGF and c-Met expression in epithelial tumour cells in EC patients regarding the presence of metastasis. However, an increased expression of HGF was detected in the stromal fibroblasts of EC patients with metastasis compared to those without metastasis (24.3 ± 6.0 and 2.8 ± 1.3%, respectively, p <0.05). In addition, in patients with metastasis, c-Met expression was higher in stromal fibroblasts of carcinomas that invaded 50% or more of the myometrium in contrast to the cases with less than 50% myometrial invasion (27.8 ± 6.8 and 0.9 ± 0.5%, p <0.05).

Conclusions

Increased expression of HGF and c-Met in stromal fibroblasts of endometrial carcinomas is associated with the presence of metastasis and may be coincide with deep myometrial invasion in EC patients. Obtained results revealed that stromal expression of these proteins might contribute to the aggressiveness of EC.

Legal entity responsible for the study

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Science of Ukraine, Kyiv, Ukraine.

Funding

National Academy of Science of Ukraine, Kyiv, Ukraine.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings